PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Transplantation and Cellular Therapy0 citations

Cord Blood Transplant with Abatacept and Low-Dose ATG for TP53-Mutated Complex Karyotype AML: A Single-Center Report

View Full Paper
RYRachael YasudaThe University of Texas MD Anderson Cancer CenterNDNicolas DePadovaThe University of Texas MD Anderson Cancer CenterHPHaley PeblerThe University of Texas MD Anderson Cancer Center

Key Points

  • Cord blood transplant with abatacept and low-dose ATG showed improved outcomes in TP53-mutated AML.
  • The combination treatment led to significant survival rates, with 80% of patients alive at one year.
  • Observational analysis at a single center included patients with complex karyotype AML, focusing on their response to the treatment.
  • Implications highlight the need for further studies to validate efficacy and explore long-term effects of the approach.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yasuda et al. (2026) studied this question.

synapsesocial.com/papers/69a7609bc6e9836116a2d864https://doi.org/10.1016/j.jtct.2025.12.587
Ask AI
Helpful
Bookmark
Share
View Full Paper